Patents Assigned to KaNDy Therapeutics Limited
-
Patent number: 12264164Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: GrantFiled: July 31, 2023Date of Patent: April 1, 2025Assignee: KANDY THERAPEUTICS LIMITEDInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Publication number: 20230382922Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: ApplicationFiled: July 31, 2023Publication date: November 30, 2023Applicant: KaNDy Therapeutics LimitedInventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
-
Patent number: 11787820Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: GrantFiled: August 4, 2020Date of Patent: October 17, 2023Assignee: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Patent number: 11767328Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: GrantFiled: January 13, 2023Date of Patent: September 26, 2023Assignee: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Publication number: 20230174552Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: ApplicationFiled: January 13, 2023Publication date: June 8, 2023Applicant: KaNDy Therapeutics LimitedInventors: Mike TROWER, Monica LAZARO, Derek BUSH, David ELDER, Mary KERR
-
Patent number: 11591346Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: GrantFiled: August 4, 2020Date of Patent: February 28, 2023Assignee: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Publication number: 20230002322Abstract: The invention relates to a new process for producing compound 2-(3,5-bis(trifluoromethyl)phenyl)-N-(6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl)-N,2-dimethylpropanamide (Compound IX) which is useful in the manufacture of compound 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide (Compound A).Type: ApplicationFiled: November 9, 2020Publication date: January 5, 2023Applicant: KaNDy Therapeutics LimitedInventors: Marcel SCHLEUSNER, Massimo GHIZZONI, Ron LAWRENCE
-
Publication number: 20210236506Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.Type: ApplicationFiled: February 10, 2021Publication date: August 5, 2021Applicant: KaNDy Therapeutics LimitedInventor: Mike Trower
-
Publication number: 20210128574Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.Type: ApplicationFiled: November 6, 2018Publication date: May 6, 2021Applicant: KaNDy Therapeutics LimitedInventor: Mike Trower
-
Publication number: 20200361957Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Applicant: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Publication number: 20200361956Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis (trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Applicant: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Patent number: 10774091Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: GrantFiled: March 13, 2019Date of Patent: September 15, 2020Assignee: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
-
Publication number: 20190284205Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.Type: ApplicationFiled: March 13, 2019Publication date: September 19, 2019Applicant: KaNDy Therapeutics LimitedInventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr